Arvinas to Participate in Upcoming Investor Conferences
Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two major investor conferences. The company will be present at the Guggenheim Securities Healthcare Innovation Conference on November 13, where Chief Medical Officer Noah Berkowitz and Chief Business Officer Randy Teel will join a fireside chat. Additionally, on November 19, Berkowitz and Chief Financial Officer Andrew Saik will participate in a fireside chat at the Jefferies London Healthcare Conference. Live audio webcasts of both presentations will be accessible through the company's website and dedicated links.
Arvinas (NASDAQ: ARVN), un'azienda biotech in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato la sua partecipazione a due importanti conferenze per investitori. L'azienda sarà presente alla Guggenheim Securities Healthcare Innovation Conference il 13 novembre, dove il Direttore Medico Noah Berkowitz e il Direttore Commerciale Randy Teel parteciperanno a una chiacchierata informale. Inoltre, il 19 novembre, Berkowitz e il Direttore Finanziario Andrew Saik parteciperanno a una chiacchierata informale alla Jefferies London Healthcare Conference. Le webcasting audio dal vivo di entrambe le presentazioni saranno accessibili tramite il sito web dell'azienda e link dedicati.
Arvinas (NASDAQ: ARVN), una empresa biotecnológica en etapa clínica centrada en la degradación selectiva de proteínas, ha anunciado su participación en dos importantes conferencias para inversionistas. La empresa estará presente en la Guggenheim Securities Healthcare Innovation Conference el 13 de noviembre, donde el Director Médico Noah Berkowitz y el Director de Negocios Randy Teel se unirán a una charla informal. Además, el 19 de noviembre, Berkowitz y el Director Financiero Andrew Saik participarán en una charla informal en la Jefferies London Healthcare Conference. Las transmisiones web de audio en vivo de ambas presentaciones estarán disponibles a través del sitio web de la empresa y enlaces dedicados.
Arvinas (NASDAQ: ARVN), 표적 단백질 분해에 중점을 둔 임상 단계의 바이오텍 회사가 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 회사는 11월 13일 Guggenheim Securities Healthcare Innovation Conference에 참석할 예정이며, 이 자리에서 최고 의학 책임자 노아 버코위츠와 최고 사업 책임자 랜디 틸이 편안한 대화에 참여합니다. 또한 11월 19일에는 버코위츠와 최고 재무 책임자 앤드류 사이크가 Jefferies London Healthcare Conference에서 편안한 대화에 참석합니다. 두 발표의 실시간 오디오 웹 캐스트는 회사 웹사이트와 전용 링크를 통해 접근할 수 있습니다.
Arvinas (NASDAQ: ARVN), une entreprise biopharmaceutique en phase clinique spécialisée dans la dégradation ciblée des protéines, a annoncé sa participation à deux grandes conférences pour investisseurs. L'entreprise sera présente à la Guggenheim Securities Healthcare Innovation Conference le 13 novembre, où le Directeur Médical Noah Berkowitz et le Directeur Commercial Randy Teel participeront à une discussion informelle. De plus, le 19 novembre, Berkowitz et le Directeur Financier Andrew Saik participeront à une discussion informelle lors de la Jefferies London Healthcare Conference. Des webdiffusions audio en direct des deux présentations seront accessibles via le site web de l'entreprise et des liens dédiés.
Arvinas (NASDAQ: ARVN), ein klinisches Biotech-Unternehmen, das sich auf die gezielte Proteinabbau konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 13. November auf der Guggenheim Securities Healthcare Innovation Conference präsent sein, wo der Chief Medical Officer Noah Berkowitz und der Chief Business Officer Randy Teel an einem informellen Gespräch teilnehmen werden. Darüber hinaus werden Berkowitz und der Chief Financial Officer Andrew Saik am 19. November an einem informellen Gespräch auf der Jefferies London Healthcare Conference teilnehmen. Live-Audio-Webcasts beider Präsentationen sind über die Unternehmenswebsite und spezielle Links zugänglich.
- None.
- None.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
- Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13.
- Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
- Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
- Jefferies London Healthcare Conference on Tuesday, November 19.
- Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
What investor conferences will Arvinas (ARVN) attend in November 2024?
Who will represent Arvinas (ARVN) at the Guggenheim Securities Healthcare Conference?
How can investors access Arvinas (ARVN) conference presentations in November 2024?
Which executives will participate in Arvinas (ARVN) Jefferies London Healthcare Conference?
